Dr. Reggia, et al, reply

To the Editor: We are pleased that our article1 has aroused interest from colleagues and we thank them for providing us valuable input for further analysis. We have considered the data presented by Monti, et al 2 in their Letter to the Editor regarding the good outcome obtained in a cohort of 21 patients after the switch from the intravenous (IV) to the subcutaneous (SC) formulation of abatacept (ABA). In their study, the risk of disease relapse appears to be lower than in our experience, even though about 40% of their patients presented moderate disease activity at the end of followup (6 mos after the switch). Within these, 21 patients (10%) showed an objective disease worsening. However, in general terms, the disease activity achieved during IV … Address correspondence to Dr. R. Reggia, Piazzale Spedali Civili 1, 25123 Brescia, Italy. E-mail: rossella.reggia{at}gmail.com